Nephrol Dial Transplant (2001) 16: 1442-1447
© 2001 European Renal Association-European Dialysis and Transplant Association
Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response
Department of Nephrology and Internal Medicine, Medical Academy, Bialystok, Poland
Background. Increased plasma soluble von Willebrand factor antigen (vWF : Ag) level, a marker of vascular endothelial cell dysfunction, is a strong predictor of atherosclerotic cardiovascular disease (CVD) in the general population. We studied cross-sectional associations between vWF : Ag level, prevalence of CVD, and related factors including pre-dialysis arterial blood pressure (BP) and some markers of inflammation in maintenance haemodialysis (HD) patients.
Methods and results. Plasma vWF : Ag level measured by an enzyme-linked immunosorbent assay (ELISA) was higher in 110 HD patients than in 20 controls. On bivariate regression analysis, vWF : Ag level was directly associated with the presence of CVD, age, fibrinogen and the use of enoxaparin (vs unfractionated heparin) during HD procedures, and inversely with albumin and pre-dialysis BP. The patients with prevalent CVD were older, had higher vWF : Ag, white blood cell and platelet counts, fibrinogen and triglycerides, lower albumin levels, and were less frequently on combination antihypertensive therapy. Multivariable analyses identified low pre-dialysis BP, hypoalbuminaemia and hyperfibrinogenaemia (in descending order of significance) as independent predictors of high vWF : Ag level. There were no associations between vWF : Ag levels and gender, ABO blood type, smoking, body mass index, renal failure cause, duration of HD therapy, Kt/V, normalized protein catabolic rate, dialysate buffers, dialysers, viral hepatitis, erythropoietin treatment, specific antihypertensive drugs, haemoglobin, white blood cell and platelet counts, liver enzymes, phosphorous, total cholesterol, and triglycerides.
Conclusion. Elevated plasma levels of endothelial dysfunction marker vWF : Ag in maintenance HD patients are associated with established cardiovascular mortality risk factors such as low pre-dialysis blood pressure and the activated acute phase response.
Keywords: acute phase response; blood pressure; cardiovascular disease; endothelium; haemodialysis; von Willebrand factor
Correspondence and offprint requests to: Dr Jacek Borawski, Department of Nephrology and Internal Medicine, Medical Academy, 14 Zurawia Street, PL 15-540 Bialystok, Poland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Kwon, S.-M. Hong, T. A. Sutton, and C. J. Temm Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury Am J Physiol Renal Physiol, August 1, 2008; 295(2): F351 - F359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. C. Grooteman, M. Gritters, I. M. P. M. J. Wauters, C. G. Schalkwijk, F. Stam, J. Twisk, P. M. ter Wee, and M. J. Nube Patient characteristics rather than the type of dialyser predict the variability of endothelial derived surface molecules in chronic haemodialysis patients Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2751 - 2758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Borawski, B. Naumnik, and M. Mysliwiec Liver disease vs systemic inflammation in haemodialysis patients Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1277 - 1278. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Stasko and P. Kubisz Increased Soluble Thrombomodulin in Hemodialysis Patients with Long-term Erythropoietin Treatment: What Does it Reflect? Clinical and Applied Thrombosis/Hemostasis, October 1, 2003; 9(4): 349 - 352. [PDF]
|
|
|
|
 |
|
 A. Woywodt, M. Schroeder, M. Mengel, A. Schwarz, W. Gwinner, H. Haller, and M. Haubitz Circulating Endothelial Cells Are a Novel Marker of Cyclosporine-Induced Endothelial Damage Hypertension, March 1, 2003; 41(3): 720 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Borawski, B. Naumnik, and M. Mysliwiec Tissue Factor and Thrombomodulin in Hemodialysis Patients: Associations with Endothelial Injury, Liver Disease, and Erythropoietin Therapy Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 359 - 367. [Abstract] [PDF]
|
|
|
|
|
|
B. Naumnik, J. Borawski, K. Pawlak, and M. Mysliwiec Effect of Hemodialysis on Plasma Levels of Vascular Endothelial Markers Clinical and Applied Thrombosis/Hemostasis, July 1, 2002; 8(3): 245 - 250. [Abstract] [PDF]
|
|
|
|
|
|
J. Borawski and M. Mysliwiec Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients Nephrol. Dial. Transplant., April 1, 2002; 17(4): 637 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Borawski and M. Mysiwiec Effects of Recombinant Erythropoietin Therapy on Circulating Endothelial Markers in Hemodialysis Patients Clinical and Applied Thrombosis/Hemostasis, January 1, 2002; 8(1): 77 - 84. [Abstract] [PDF]
|
|